Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases

Respiratory Research

Table 1 Baseline characteristics of subgroups taking high-dose, low-dose, or no glucocorticoids at baseline

	High-dose glucocorticoids (n = 8)	Low-dose glucocorticoids (n = 353)	No glucocorticoids (n = 302)
Male	2 (25.0)	189 (53.5)	165 (54.6)
Age, years	61.8 (4.2)	65.5 (10.0)	66.2 (9.6)
Former or current smoker	3 (37.5)	173 (49.0)	162 (53.6)
ILD diagnosis
Hypersensitivity pneumonitis	5 (62.5)	96 (27.2)	72 (23.8)
Autoimmune ILDs^a	1 (12.5)	114 (32.3)	55 (18.2)
iNSIP	0	65 (18.4)	60 (19.9)
Unclassifiable IIP	2 (25.0)	41 (11.6)	71 (23.5)
Other ILDs^b	0	37 (10.5)	44 (14.6)
FVC, mL	1744 (546)	2287 (696)	2397 (771)
FVC, % predicted	53.8 (6.9)	67.4 (14.9)	71.2 (16.2)
DLco, % predicted	44.4 (9.1)	44.4 (12.6)	48.2 (14.6)

Data are shown as n (%) or mean (SD). Glucocorticoids with oral, intravenous, intravenous bolus, intravenous drip, or intramuscular route of administration. High-dose glucocorticoids: > 20 mg/day prednisone or equivalent
DLco: diffusing capacity of the lung for carbon monoxide, corrected for hemoglobin; FVC: forced vital capacity; IIP: idiopathic interstitial pneumonia; ILD: interstitial lung disease; iNSIP: idiopathic non-specific interstitial pneumonia; MCTD: mixed connective tissue disease; RA: rheumatoid arthritis; SSc: systemic sclerosis
^aIncluded RA-ILD, SSc-ILD, MCTD-ILD, plus autoimmune ILDs in the “Other fibrosing ILDs” category of the case report form
^bIncluded sarcoidosis, exposure-related ILDs and selected other terms in the “Other fibrosing ILDs” category of the case report form

ISSN: 1465-993X